Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD5 | P21918 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL17364147 | 0.93 | SIGMAR1 (0.44) | DRD2DRD3DRD1DRD4DRD5 | |
| Sulfuric Acid SCHEMBL17364146 | 0.90 | SIGMAR1 (0.41) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL20691283 | 0.86 | HTR1A (0.41) | DRD2DRD3SIGMAR1HTR1AHTR6 | |
| SCHEMBL18395651 | 0.86 | SIGMAR1 (0.41) | DRD2DRD3SIGMAR1HTR1AHTR6 | |
| SCHEMBL17411300 | 0.83 | HTR1A (0.51) | DRD2DRD3SIGMAR1HTR1AHTR6 | |
| SCHEMBL29363627 | 0.81 | SIGMAR1 (0.60) | DRD2DRD3DRD4SIGMAR1HTR1A | |
| SCHEMBL26666901 | 0.81 | SIGMAR1 (0.45) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL30690009 | 0.81 | SIGMAR1 (0.45) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL11278195 | 0.78 | HTR7 (0.55) | DRD2SIGMAR1HTR1AKCNA3 | |
| SCHEMBL17364187 | 0.77 | SIGMAR1 (0.40) | SIGMAR1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250233-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2025-08-07 | — | — | US | disclosed |
| EP-4519246-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE | Prilenia Neurotherapeutics Ltd. (IL) | 2025-03-12 | — | — | EP | disclosed |
| CN-119137100-A | Process and intermediates for the preparation of pridopidine | 普瑞尼亚神经治疗有限公司 | 2024-12-13 | — | — | CN | disclosed |
| WO-2023214412-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2023-11-09 | — | — | WO | disclosed |
| EP-3325443-B1 | PROCESS FOR PREPARING PRIDOPIDINE | Prilenia Neurotherapeutics Ltd (IL) | 2022-06-08 | — | — | EP | disclosed |
| US-20220023280-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | PRILENIA NEUROTHERAPEUTICS LTD. | 2022-01-27 | — | — | US | disclosed |
| CN-113511997-A | Pridopidine analogues, their preparation and use | 普丽莱尼亚神经治疗有限公司 | 2021-10-19 | — | — | CN | disclosed |
| US-11141412-B2 | Analogs of pridopidine, their preparation and use | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2021-10-12 | — | — | US | disclosed |
| US-20200030308-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | PRILENIA NEUROTHERAPEUTICS LTD. | 2020-01-30 | — | — | US | disclosed |
| US-10406145-B2 | Analogs of pridopidine, their preparation and use | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2019-09-10 | — | — | US | disclosed |
| US-9139525-B2 | N-oxide and/or di-N-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2015-09-22 | — | — | US | disclosed |
| US-7923459-B2 | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-N-propyl-piperidine | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-04-12 | — | — | US | disclosed |
| US-7923459-B2 | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-N-propyl-piperidine | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-04-12 | — | — | US | disclosed |
| US-20100105736-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-04-29 | — | — | US | disclosed |
| US-20100105736-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-04-29 | — | — | US | disclosed |
| US-20100105736-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-04-29 | — | — | US | disclosed |
| WO-2008127188-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | ALLBAY AB (SE) | 2008-10-23 | — | — | WO | disclosed |
| US-20070238879-A1 | PROCESS FOR THE SYNTHESIS OF 4-(3-METHANESULFONYLPHENYL)-1-N-PROPYL-PIPERIDINE | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2007-10-11 | — | — | US | disclosed |
| US-20070238879-A1 | PROCESS FOR THE SYNTHESIS OF 4-(3-METHANESULFONYLPHENYL)-1-N-PROPYL-PIPERIDINE | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2007-10-11 | — | — | US | disclosed |
| WO-2006040155-A1 | PROCESS FOR THE SYNTHESIS OF 4-(3-METHANESULFONYLPHENYL)-1-N-PROPYL-PIPERIDINE | NEUROSEARCH SWEDEN AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105736-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | CHRM4, GPR4, HTR4 | DRD2 66/4885DRD3 37/4885DRD1 153/4885 |
| US-11141412-B2 | Analogs of pridopidine, their preparation and use | PDE7A, PDE3A, PDE4D | DRD2 7/4885DRD3 21/4885DRD1 34/4885 |
| US-10406145-B2 | Analogs of pridopidine, their preparation and use | QDPR, DRD2, OPRD1 | DRD2 2/4885DRD3 5/4885DRD1 9/4885 |
| US-20250250233-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE | QDPR, MAOB, DRD2 | DRD2 3/4885DRD3 33/4885DRD1 24/4885 |
| US-20200030308-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | QDPR, DRD2, OPRD1 | DRD2 2/4885DRD3 5/4885DRD1 8/4885 |
| US-20220023280-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | PDE3A, PDE4D, PDE9A | DRD2 14/4885DRD3 30/4885DRD1 40/4885 |
| US-20070238879-A1 | PROCESS FOR THE SYNTHESIS OF 4-(3-METHANESULFONYLPHENYL)-1-N-PROPYL-PIPERIDINE | GPX4, SQOR, SRM | DRD2 1056/4885DRD3 1244/4885DRD1 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.